Iron absorption enhancement

Iron absorption enhancement" is a functional process—not a discrete molecule, gene, or receptor—and is commonly referred to in pharmacology and nutrition as the facilitation or increase of iron uptake from the gut, usually by targeting underlying molecular mechanisms such as transporters (notably DMT1/SLC11A2) and reductases (such as Dcytb) in intestinal enterocytes[9][7][2][1]. Agents like vitamin C are known to enhance iron absorption by maintaining iron in its ferrous (Fe2+) state, which is more readily transported by DMT1 after reduction by Dcytb[1][7]. Peptide–iron chelates, hepcidin antagonists, and gastric acidifiers are other means for enhancing iron bioavailability[9][7]. If the intention was to identify a molecular target related to enhancement of iron absorption, Divalent metal transporter 1 (DMT1)/SLC11A2 or Duodenal cytochrome b (Dcytb) should be specified instead[2][1][6][7]. Otherwise, "iron absorption enhancement" itself cannot be structured as a canonical target entity.